All News
Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease
There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.
Read Article
Mavrilimumab (anti-GM-CSF) metanalysis shows gret benefit in #RA - 1145 pts, 3 trials shows significant 12 week responses by: 1) DAS28-CRP remission (RR = 3.31); 2) ACR20 (RR = 2.38); 3) ACR50 (RR = 2.93) & 4) ACR70 (RR = 4.9). Where is it? https://t.co/9L5PFEB1DI
Links:
Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis faculty panel with audience Q&A #RNL2021 https://t.co/iSosAtHLCZ
Dr. John Cush RheumNow ( View Tweet)
Follow the hashtag #RNL2021 for all RheumNow Live coverage today!
Dr. John Cush RheumNow ( View Tweet)
Dr. Artie Kavanaugh leading the spondyloarthritis pod focusing on enthesitis and dactylitis management. #RNL2021 https://t.co/NCUwabTXVd
Dr. John Cush RheumNow ( View Tweet)
Join me at the @RheumNow SpA session happening now! #rheumatology #spondyloarthritis #ankylosing https://t.co/CTLq0xWQys
Nigil Haroon MD, PhD 💎🦜🌎🩺🔬 NigilHaroon ( View Tweet)
Leading the Rheumatoid Arthritis pod with discussions on pneumonia and RA and interstitial lung disease in RA. #RNL2021 https://t.co/psxMTHsOva
Dr. John Cush RheumNow ( View Tweet)
New podcast available! Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.
https://t.co/rPnLp2NfRq https://t.co/TSTP2tWxXy
Links:
Dr. John Cush RheumNow ( View Tweet)
Our in-person participants engaging with the psoriatic panel #RNL2021 https://t.co/N0Cdos3Rhb
Dr. John Cush RheumNow ( View Tweet)
News Feature: Potent Topical Corticosteroids and the Risk of Osteoporotic Fractures
https://t.co/KazNPRXKNx https://t.co/pykBdbexzF
Links:
Dr. John Cush RheumNow ( View Tweet)
@RheumNow #RNL2021 Dr. Buttgereit on steroids in RA:
2.5 mg/d of prednisone increase total steroid amount in the body by 100% - great therapeutic effect but comes w/plethora of side effects.
Q: how do you feel out long term low dose steroids for RA?
Olga Petryna DrPetryna ( View Tweet)
Follow the hashtag #RNL2021 for all RheumNow Live coverage today and tomorrow!
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live has started! #RNL2021 https://t.co/CrNqnnKqUy
Dr. John Cush RheumNow ( View Tweet)
Metanalysis reveals significant heterogeneity in defining Refractory Disease in RA and polyarticular JIA. Should include: 1) Resistance to multiple drugs w/ different MOAs (≥2bDMARDs) and 2) Persistent symptoms and disease activity https://t.co/CL6Mr3cs7J
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: Are You a Super Rheum?
https://t.co/LsGpFNXlkp https://t.co/Q9iojEQNqL
Links:
Dr. John Cush RheumNow ( View Tweet)
Top 4 arthritis types that significantly increase the risk of CVA: 1) RA (RR=1.38), 2) ankylosing spondylitis (RR=1.49), 3) psoriatic arthritis (RR=1.33) & gout (RR=1.4). With these, the risk was higher in younger (<45 yrs) (RR = 1.46), not older (>65) https://t.co/Snb6OrtZJH
Links:
Dr. John Cush RheumNow ( View Tweet)
NAFLD, NASH and Risks with DMARDs and MTX
https://t.co/LYV9WycEjz https://t.co/Vx0jvhjCsd
Links:
Dr. John Cush RheumNow ( View Tweet)
Kiniksa announced Arcalyst (rilonacept) has been FDA-approved for the treatment of recurrent pericarditis. Rilonacept, an IL-1 inhibitor, also FDA approved for CAPS (Cryopyrin-Assoc Periodic Syndr) & DIRA (Defic IL-1 Recept Antag) https://t.co/erpiyuhsAv https://t.co/xp764WkWEI
Dr. John Cush RheumNow ( View Tweet)
News Feature: MDA-5 Antibodies and Juvenile Dermatomyositis
https://t.co/vxyXZyO0gs https://t.co/GgzhnhlmdR
Links:
Dr. John Cush RheumNow ( View Tweet)
SPIRIT‐P3 RCT treated biologic‐naive PsA with ixekizumab x36 wks; those w/ MDA x 3 mos were randomized to continue or withdraw IXE (blinded). There were significantly more relapses when IXE was stopped; most regained control when started https://t.co/lhQ8X1Ef48
Links:
Dr. John Cush RheumNow ( View Tweet)
